Désirée van der Heijde discusses the results of SELECT-AXIS 1, a phase II/III trial demonstrating that upadacitinib may be a promising treatment option for ankylosing spondylitis (2:27). External Content Click Play to display this content and agree to third party cookies. (>) Update your current cookie settings. Transcript